Suchi Acharya, PhD
Founder and CEO
Dr. Suchismita Acharya is the Founding President of AyuVis Research. Prior to AyuVis, She spent 15 years in various leadership roles with Alcon Labs (Novartis) and led projects from early stage to pre-clinical in glaucoma, AMD and anti-viral diseases.
She is an innovative scientist with the ambition of adding first in-class small molecules for ocular as well as anti bacterial/viral diseases to AyuVis’ research and drug discovery portfolio. She is a certified Project Manager and managed drug discovery projects from hit to lead, lead optimization and lead the project through phase-I-III clinical trials in humans.
Keith Bryant, MBA
Chief Business Officer
Initially a Booz.Allen & Hamilton strategy consultant in New York focused on big pharma, Keith Bryant has over 20 years’ experience in Business Planning, Business Development and Finance in biotech across many therapeutic areas and scientific modalities.
He has closed a total of 10 deals from both sides of the table including a $1.4 billion out-licensing and has closed 5 successful financings ranging from $250,000 to $75 million. He is a past member of the leadership teams of 4 mid-sized public companies and has counseled and led multiple start-ups from early proof-of-concept to a strong business foundation. He holds an MBA in Finance from NYU and other degrees from Texas Tech University and Yale.
Russell Bromley, BA
Director of Operations
Mr. Russell Bromley brings us 30 years of management experience in life science research and healthcare.
Mr. Bromley has an undergraduate degree in Biochemistry from Rice University. He has experience as a consultant, founder, CEO, COO, and president to biomedical research institutions, foundations and companies in healthcare, IT and high-tech manufacturing, including 17 years with Baxter Healthcare.
David Riley, MD, MBA
Chief Medical Officer
Dr. David Riley is board certified in pediatrics and neonatal-perinatal medicine at Cook's Children Hospital in Fort Worth, TX.
Dr. Riley received his undergraduate degree in Biochemistry from Cornell University, medical degree from Stanford University School of Medicine, completed his pediatric residency at the University of North Carolina Hospitals, and neonatal-perinatal fellowship at the University of Texas in Houston. His research interests include neonatal immunology and infectious disease, respiratory physiology and evidenced based medicine.
Dennis Dean, PhD
Head of CMC
Dr. Dennis Dean is an innovative process chemist with 30+ years experience in synthetic organic chemistry, heterocyclic chemistry, process development, route selection, and optimization and process validation. He is experienced in the synthesis of small molecules for medicinal uses such as steroids, prostaglandins, heterocycles, peptides and nucleotides.
In addition, he has extensive experience in CMC and compliance areas as they relate to GMP API manufacturing, in particular APIs for clinical development. This includes regulatory filings and GMP audits of API manufacturers.
Darlene Boudreaux, CPA, MBA
Fractional Chief Financial Officer
Ms. Darlene Boudreaux is a retired pharmaceutical entrepreneur, accountant, the former Executive Director of TechFW, and current CFO of TechFW.
She received a Bachelors degree in Math and German from DePauw University and a MBA with a focus on Accounting and Finance. She works with entrepreneurs who have licensed or developed a proprietary technology, primarily new pharmaceuticals or medical devices.
Mr. Ranjan Misra has 30+ years of global business experience with large multinational and privately held companies, including general management, business development, fundraising, client management and operations.
He has also assisted private equity firms with acquisitions, divestitures, and roll-ups of portfolio companies.
Dale Christensen, PhD
Director of Early Development
Dr. Dale Christensen brings us over 25 years of of R&D VP/CSO experience from small and big pharmaceutical companies.
Dr. Christensen has an undergraduate degree in Chemistry from the University or Utah and a PhD in Chemistry from Utah State University. He has more than 20 years of experience developing novel therapeutics with an emphasis on IND-enabling toxicology and safety pharmacology studies. He specializes in developing and reviewing study protocols, managing preclinical CROs, analyzing data, and trouble-shooting toxicity, PK, and safety pharmacology studies for preclinical and IND-enabling studies.